Introduction:Incidence of Rh negative pregnancy in western countries is 15%, but in India it varies from 3% to 5.7%. It is a high risk pregnancy, as it may cause antigen-antibody reaction and haemolysis. However, it can be prevented by adequate measures. Aims and objectives: To determine feto-outcome in Rh negative pregnant women. Materials and methods: Across sectional study was carried out in the department of Obstetrics & Gynaecology and Paediatrics, Regional Institute of Medical Sciences, Imphal, Manipur for the duration of 2 years. The total of 38 Rh negative pregnant women were included in the study after applying inclusion and exclusion criteria. Results: In the present study among 38 patients, 31.6% were delivered through Elective LSCS, 26.31% were vaginally delivered and 21.1% were Emergency LSCS. Among 38 patients, 5.3% were preterm birth, 92.1% were term birth and 2.6% were post term birth. In this study, 7.9% of patients in the study group were indirect coomb' test (ICT) positive, 92% were ICT negative. Out of 38 patients, 20 were booked who received antenatal anti-D prophylaxis in contrast to 18 unbooked patients. 35 out of 38 patients received post-natal prophylaxis with 300 mcg anti-D. Perinatal outcome in 38 patients was 73.7% were healthy, NICU admission were 15.8%, intrauterine death (IUD) were 5.3% and 2.6% were neonatal death. The conventional treatment measures are appropriate hydration, phototherapy and exchange transfusion. Conclusions: Rh haemolytic disease of the new-born forms common and preventable cause of maternal and perinatal morbidity. Anti-D IgG administration and proper fetal and neonatal monitoring when required decreases the burden of disease
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.